Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience

References

• Aleva RM, Boersma WG. [Guideline ‘Diagnosis and treat-ment of community-acquired pneumonia’ from the Dutch Tho-racic Society]. Ned Tijdschr Geneeskd 2005; 149: 2501–2507.
   PubMedGoogle Scholar
• Viegi G, PisteIli R, Cazzola M et al. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med 2006; 100: 46–55.
   Google Scholar
• Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J 2002; 20: Suppl. 36: 20s-27s.
   Google Scholar
• Bartlett JG, Dowell SF.Mandell LA. Guidelines from the In-fections Diseases Society of America: practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–382.
   Google Scholar
• Fine MJ, Smith MA, Carson CA, et al. Prognosis and out-comes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134–141.
   PubMed Web of Science ®Google Scholar
• File TM, Jr., Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888–1901.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, et al. Update of prac-tice guidelines for the management of community-acquired pneu-monia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405–1433.
   PubMed Web of Science ®Google Scholar
• Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–515.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneu-monia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–1754.
   Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–1180.
   PubMed Web of Science ®Google Scholar
• (BTS) BTS. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (Suppl 4): 1-64.
   Google Scholar
• BTS Pneumonia Guidelines Committee. BTS Guidelines for the management of community acquired pneumonia in adults - 2004 update. pp. 1-22.
   Google Scholar
• Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004; 50 Suppl 1: 3–10.
   PubMed Web of Science ®Google Scholar
• Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae sus-ceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Micro-biol Infect Dis 2003; 46: 285–289.
   PubMed Web of Science ®Google Scholar
• Johnson DM, Stilwell MG, Fritsche TR, et al. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006; 56: 69–74.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, et al. Increasing preva-lence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917–1924.
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Biedenbach DJ, Mutnick AH, et al. Pathogen of occurrence and susceptibility patterns associated with pneu-monia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Micro-biol Infect Dis 2003; 45: 279–285.
   PubMed Web of Science ®Google Scholar
• Cercenado E, Cercenado S, Gomez JA, Souza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with dimin-ished susceptibility to glycopeptides. J Antimicrob Chemother 2003; 52: 138–139.
   PubMed Web of Science ®Google Scholar
• Betriu C, Culebras E, Rodriguez-Avial I, et al. In vitro ac- tivities of tigecycline against erythromycin-resistant Streptococ-cus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Che-mother 2004; 48: 323–325.
   PubMed Web of Science ®Google Scholar
• Dartois N, Gandjini H, Ellis-Grosse EJ. Tigecycline is as safe and effective as levofloxacin in treating patients with com-munity-acquired pneumonia. In: Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases (EC-CMID), Nice, France, 2006. Abstract 0223.
   Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354–367.
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The effi-cacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341–353.
   PubMed Web of Science ®Google Scholar
• Carrie AG, Kozyrskyj AL. Outpatient treatment of com-munity-acquired pneumonia: evolving trends and a focus on flu-oroquinolones. Can J Clin Pharmacol 2006; 13: e102–111.
   PubMedGoogle Scholar
• Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumo-nia. N Engl J Med 2002; 346: 747–750.
   PubMed Web of Science ®Google Scholar
• Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002; 36: 1938–1943.
   PubMed Web of Science ®Google Scholar